In both the frontline and relapsed/refractory settings, daratumumab, an anti-CD38 monoclonal antibody, was associated with higher rates of infection overall (RR 1.27; 95% CI 1.17–1.37), severe infections (RR 1.27; 95% CI 1.14–1.41), and pneumonia (RR 1.39; 95% CI 1.12–1.72) [17]. Here, CD38 is linked to infection.